We are pleased to announce that the Phase II clinical trial evaluating our novel drug, AD17002, for moderate-to-severe asthma has successfully and fully enrolled all 127 patients, achieving this milestone several months ahead of expectations. We anticipate concluding all clinical trial activities by the end of this year, which will subsequently be followed by comprehensive data analysis.

‍